Data

Medicare numbers trigger physician anger

Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.

Merck looks poised to challenge Gilead

Merck looks poised to challenge Gilead

By

Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.

Sunshine data highlights major billers

Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Study links patient confidence to Rx adherence

Study links patient confidence to Rx adherence

By

Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.

Alkermes to submit schizophrenia med this year

Phase-III results prompted the drugmaker to pursue a third-quarter filing.

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

By

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

By

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

Health reform spurs Rx growth, data show

Health reform spurs Rx growth, data show

By

The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.

Sanofi reports on Phase-II PCSK9 trial

The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.

Trials confirm potent efficacy of PCSK9s

Trials confirm potent efficacy of PCSK9s

By

Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.

Merck diversifies its Big Data agenda

Merck diversifies its Big Data agenda

By

Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.

Possible Zohydro competitor surfaces

Possible Zohydro competitor surfaces

By

A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.

EHR use up 10%, as small practices tame data crunch

EHR use up 10%, as small practices tame data crunch

By

A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.

Prevnar 13 hits goals, but impact is uncertain

Prevnar 13 hits goals, but impact is uncertain

By

Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.

Adults increasingly using ADHD medications

Adults increasingly using ADHD medications

By

Express Scripts notes that these prescriptions may not, in fact, be for ADHD.

Nexavar fails recurrence target

Nexavar fails recurrence target

By

Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.

Study shows sample-drug adherence link

Study shows sample-drug adherence link

By

A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.

New FDA Twitter feed has diverse following

@openFDA and its related website launched February 27.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

By

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Novartis enhances data access

The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.

FDA approves sNDA for Xeljanz

The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.

Lilly's GLP-1 contender takes a step forward

Lilly's GLP-1 contender takes a step forward

By

Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.

Pfizer Prevnar data could boost Rx numbers

Pfizer Prevnar data could boost Rx numbers

By

The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.

Lilly's ramu' has squamous, non-squamous potential

Lilly's ramu' has squamous, non-squamous potential

By

The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.

Study finds doctor reviews matter to some extent

Study finds doctor reviews matter to some extent

By

A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.

Janssen signs onto Yale data-sharing project

The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.

Pitting Big Data against nonadherence

Pitting Big Data against nonadherence

By

A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.

Ph.III results a boost for Amgen in PCSK9 race

Ph.III results a boost for Amgen in PCSK9 race

By

Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.

IMS to go public, says acquisitions possible

IMS to go public, says acquisitions possible

By

The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.

Email Newsletters